GlobeNewswire PharmaOriginal article
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
Trial StartPositive
AI Analysis
Summary
Moleculin CEO Walter Klemp announced a 45-subject enrollment milestone during a virtual investor segment. The announcement lacks specific details regarding trial phase, drug candidates, or clinical outcomes.
Clinical Trial Data
Patients
45
Importance:2/10
Sentiment:
0.30
clinical_trialenrollmentinvestor_update
Read the original article
Published by GlobeNewswire Pharma on June 4, 2026 12:31 PM